Last reviewed · How we verify
efavirenz containing antiretroviral regimen
efavirenz containing antiretroviral regimen is a Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 1 development. Also known as: Sustiva, BMS-561525.
At a glance
| Generic name | efavirenz containing antiretroviral regimen |
|---|---|
| Also known as | Sustiva, BMS-561525 |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- efavirenz containing antiretroviral regimen CI brief — competitive landscape report
- efavirenz containing antiretroviral regimen updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about efavirenz containing antiretroviral regimen
What is efavirenz containing antiretroviral regimen?
efavirenz containing antiretroviral regimen is a Small molecule drug developed by Bristol-Myers Squibb.
Who makes efavirenz containing antiretroviral regimen?
efavirenz containing antiretroviral regimen is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).
Is efavirenz containing antiretroviral regimen also known as anything else?
efavirenz containing antiretroviral regimen is also known as Sustiva, BMS-561525.
What development phase is efavirenz containing antiretroviral regimen in?
efavirenz containing antiretroviral regimen is in Phase 1.
Related
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Also known as: Sustiva, BMS-561525
- Compare: efavirenz containing antiretroviral regimen vs similar drugs
- Pricing: efavirenz containing antiretroviral regimen cost, discount & access